Roche shares drop as oral breast cancer drug fails in trial

Roche shares fell more than 5% after its experimental breast cancer drug giredestrant failed to show benefit in newly diagnosed patients. The clinical setback undermines a previously promising candidate and may delay or reduce potential future revenue from the asset, weighing on company fundamentals and investor sentiment.

Analysis

Roche shares fell more than 5% after its experimental breast cancer drug giredestrant failed to show benefit in newly diagnosed patients. The clinical setback undermines a previously promising candidate and may delay or reduce potential future revenue from the asset, weighing on company fundamentals and investor sentiment.